ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

IOM To Form Committee To Investigate Duke Genomics Research

October 1, 2010

Number of Cancer Deaths Rise Slightly Due To Population Growth And Aging.

February 22, 2008

DCPC Board Approves Concepts For New Master Agreement, Recompetitions

October 9, 1987

Racial Disparities Persist In Diagnosis Of Advanced Breast Cancer, Colon Cancer

February 26, 2010

Cooperative Groups: Group Affiliates, Statistical Offices At Top Of NCI’s Most Needy Cases List

November 13, 1998

Satcher Calls For Wider Use Of Smoking Prevention Efforts.

September 29, 2000